Navigation Links
Lixte Biotechnology Holdings' Lead Compound, LB-1.2, Enhances the Effectiveness of Standard Cancer Chemotherapy in Animal Models
Date:7/2/2009

EAST SETAUKET, N.Y., July 2 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte. The report was published online in the early edition (June 29) of the Proceedings of the National Academy of Science (US). The print version will appear July 14.

Dr. John S. Kovach, President and CEO of Lixte, said "LB-1.2 exerts anti-cancer activity directly on the cancer cell and, more dramatically, by preventing cancer cells from recovering from DNA-damage produced by standard anti-cancer drugs. In mouse models, LB-1.2 plus Temozolomide caused complete regression without recurrence in 50 % of animals bearing tumors of human glioblastoma multiforme (GBM), the most common and aggressive brain tumor of adults, and also, marked regression of neuroblastoma, the most common cancer of children. Temozolomide, the standard drug for the treatment of patients with GBM, by itself caused regression but with recurrence of all tumors."

Dr. Kovach added "that, since LB-1.2 has a biochemical action similar to an older drug used for anticancer treatment for many years in China, we are cautiously optimistic that LB-1.2 will be well tolerated by cancer patients and hopefully, will potentially be as effective as it is in animal models of human cancer. We believe that adding LB-1.2 may be a general method for improving the effectiveness of several standard anticancer drugs not only against tumors of the brain and neural tissue but also against other cancers sensitive to drugs that work by damaging DNA. Safe
'/>"/>

SOURCE Lixte Biotechnology Holdings
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
3. Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
4. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Johnson & Johnson Announces Regulatory Clearance for Its Planned Acquisition of Cougar Biotechnology
7. A-WIT Technologies Releases World's First Low Cost C Stamp(TM) Based Biotechnology Laboratory in a Box
8. Yongye Biotechnology International Receives License to Manufacture Products
9. Johnson & Johnson Begins Tender Offer to Acquire Cougar Biotechnology
10. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
11. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... Illinois (PRWEB) December 22, 2014 ITRA ... tenants and occupiers of commercial real estate, has further ... new offices in Perth and Brisbane, Western Australia, reports ... of directors. , ITRA Global / ACORPP (Australian ... totally independent consultancy company providing property services to a ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... PALO ALTO, Calif., Oct. 26 Telik, Inc. (Nasdaq: ... HCl), the company,s lead therapeutic product candidate, has been ... of "The Top 10 Most Interesting Oncology Projects to ... to senior executives in the pharmaceutical, biotechnology, and medical ...
... Genomic Health , Inc. (Nasdaq: GHDX ) ... webcast on Monday, November 8 at 4:30 p.m. Eastern Time to ... will follow the release of the third quarter financial results after ... To access the live conference call on November 8 ...
... Pharmaceuticals, Inc. (Nasdaq: OPTR ) is scheduled ... the Waldorf-Astoria Hotel in New York City on Tuesday, ... (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) (Logo: ... presentation will be accessible on the Company,s website at ...
Cached Biology Technology:TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 2TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 3Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010 2Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference 2
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... -- As part of our commitment to offering the ... announce the release of a new reader that will ... data that they need. The Atlas 2000 ... readers. Many such devices have serious shortcomings when it ... models force users to navigate numerous complicated steps in ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... may have found a way to dramatically slow organ ... That's the promising implication of an animal study carried ... Birmingham (UAB) and the University of Florida (UF) published ... National Academy of Sciences. , The research team reported ...
... A drug first used to reduce the risk of stomach ... alternative to surgery after miscarriage, according to a study by ... Development of the National Institutes of Health and other research ... New England Journal of Medicine. , The drug, misoprostol, has ...
... protein design by a University of Houston professor will ... Nano Summit Research Conference July 28. , Kurt L. ... UH, will give a presentation at 11 a.m. on ... by the Nanotechnology Foundation of Texas, the 2005 Nano ...
Cached Biology News:Discoveries by UAB and Florida scientists may help transplanted organs survive longer 2Drug Offers Alternative to Surgical Treatment After Miscarriage 2Drug Offers Alternative to Surgical Treatment After Miscarriage 3Drug Offers Alternative to Surgical Treatment After Miscarriage 4Disease diagnosis, bioengineering covered at state nano summit 2
... Kit provides a fast and simple procedure for ... buffer exchange, and for removing different types of ... on spin-column chromatography using Norgens patented protein resin ... 2 , NaCl, KCl, CaCl 2 , LiCl, ...
... Surveyor software provides local instrument control ... HPLC Systems. The software operates on ... Windows Pocket PC 2002 O/S and ... directly to their Surveyor quaternary gradient ...
... Kit is a very sensitive immunohistochemical tool ... containing both anti-von Willebrand Factor and anti-CD31 ... variety of species. This AP kit provides ... of frozen and paraffin-embedded sections in human ...
... and MDS Sciex present the 4000 ... performance hybrid triple quadrupole/linear ion trap ... drug development or proteomics researcher. Innovative ... the leaders in mass spectrometry brings ...
Biology Products: